Octapharma USA
Octapharma USA is a leading healthcare company dedicated to providing innovative health solutions that advance human life. As the largest privately owned plasma fractionator globally, Octapharma develops and manufactures high-quality human proteins sourced from human plasma and cell lines, focusing on hematology, immunotherapy, and critical care. The company is committed to patient engagement and community support, ensuring that their products meet the highest safety and quality standards.
Octapharma USA
What We Do
Octapharma Plasma, Inc. collects, tests, and supplies human blood plasma for the manufacture of life-saving therapies, operating 86 donation centers across 30 states in the USA.
Octapharma conducts pre-clinical and clinical research to develop new products and ensure their safety, focusing on areas with significant unmet medical needs.
Octapharma actively engages with patients and supports organizations worldwide to improve the lives of those relying on their therapies.
Pooled Plasma (Human), Solvent/Detergent Treated Solution for Intravenous Infusion, indicated for the replacement of multiple coagulation factors in patients with acquired deficiencies.
Prothrombin Complex Concentrate, indicated for the urgent reversal of acquired coagulation factor deficiency induced by vitamin K antagonist therapy.
Fibrinogen (Human) Lyophilized Powder for Reconstitution, indicated for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
Regenerative Medicine
News & Updates
Octapharma USA received FDA Emergency Use Authorization for octaplasLG Powder, allowing U.S. military medical providers to use it in emergencies for hemorrhage or coagulopathy.
JAMA Network Open published study results demonstrating the efficacy and safety of Balfaxar® for warfarin reversal in urgent surgery and invasive procedures.
FDA approved an additional indication for Fibryga® for fibrinogen supplementation in bleeding patients with acquired fibrinogen deficiency.
FDA granted orphan drug exclusivity to wilate®, the first VWF concentrate for prophylaxis in all types of VWD.